Company Description
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States.
The company’s lead product candidates include EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus.
It has a collaborative agreement with Imugene Limited for the development of solid tumor treatments using Imugene’s product candidate CF33-CD19t in conjunction with EB103.
Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California.
| Country | United States |
| Founded | 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Cheng Liu |
Contact Details
Address: 5858 Horton Street, Suite 370 EmeryVille, California 94608 United States | |
| Phone | 510 318 9098 |
| Website | estrellabio.com |
Stock Details
| Ticker Symbol | ESLA |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001844417 |
| ISIN Number | US2975841048 |
| Employer ID | 86-1314502 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Cheng Liu Ph.D. | Chief Executive Officer, President and Director |
| Jiandong Xu | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 19, 2024 | EFFECT | Notice of Effectiveness |
| Dec 17, 2024 | 424B3 | Prospectus |
| Dec 16, 2024 | 8-K | Current Report |
| Dec 12, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Dec 9, 2024 | 424B3 | Prospectus |
| Dec 6, 2024 | 8-K | Current Report |
| Nov 27, 2024 | 424B3 | Prospectus |
| Nov 26, 2024 | 8-K | Current Report |
| Nov 25, 2024 | 8-K | Current Report |
| Nov 18, 2024 | 424B3 | Prospectus |